Company: SMNR
Filing Date: 2025-06-11
Form Type: CORRESP
Source: 0001193125-25-139135
Chunk: 7

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-06-11
Form: CORRESP
Chunk 7
---
 and Nominations, page 445

Response: The Company respectfully advises the Staff that it has revised the disclosure on page 453 of Amendment No. 2 in response to the Staff’s comment. * * * 6

U.S. Securities and Exchange Commission June 11, 2025 Please do not hesitate to contact Michael Blankenship of Winston & Strawn LLP at (713) 651-2678with any questions or comments regarding this letter.

| Sincerely, |     |                         |
| By:        |     | /s/ Lei Huang           |
|            |     | Lei Huang               |
|            |     | Chief Executive Officer |

| cc: | Michael Blankenship, Winston & Strawn LLP |

Jeff Hartlin, Paul Hastings LLP Elizabeth Razzano, Paul Hastings LLP Jaisim Shah, Chief Executive Officer and President, Semnur Pharmaceuticals, Inc. 7